Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MYC | P01106 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829035 | 0.84 | KMT2A (0.51) | KMT2AMYCALDH1A1L3MBTL1CYP2C9 | |
| SCHEMBL11400762 | 0.82 | MYC (0.58) | KMT2AMYCALDH1A1LMNATSHR | |
| SCHEMBL15434915 | 0.81 | MYC (0.66) | KMT2AMYCALDH1A1LMNATSHR | |
| SCHEMBL2209512 | 0.81 | TSHR (0.65) | KMT2AALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL27469088 | 0.80 | ALDH1A1 (0.59) | KMT2AMYCALDH1A1LMNAHSD17B10 | |
| SCHEMBL2158508 | 0.79 | ALDH1A1 (0.50) | KMT2AMYCALDH1A1LMNATSHR | |
| SCHEMBL7826927 | 0.79 | KMT2A (0.47) | KMT2AMYCALDH1A1L3MBTL1CYP2C9 | |
| SCHEMBL702149 | 0.79 | ALDH1A1 (0.59) | KMT2AALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL9911009 | 0.78 | KDM4E (0.51) | KMT2AALDH1A1L3MBTL1LMNATSHR | |
| SCHEMBL21755745 | 0.78 | KDM4E (0.49) | KMT2AMYCALDH1A1L3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116135850-A | Preparation method and application of small molecule inhibitor and compound for resisting nasopharyngeal carcinoma | 深圳湾实验室 | 2023-05-19 | — | — | CN | claimed |
| CN-113754541-B | Small molecule inhibitor of targeted EB virus nuclear antigen protein, preparation method and application thereof | 深圳湾实验室 | 2025-01-03 | — | — | CN | disclosed |
| CN-116135850-A | Preparation method and application of small molecule inhibitor and compound for resisting nasopharyngeal carcinoma | 深圳湾实验室 | 2023-05-19 | — | — | CN | disclosed |
| CN-114560862-A | Synthesis method of pyrrolo [1,2-A ] quinoxaline-4 (5H) -ketone and derivative thereof | 山东龙辰药业有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-04 | — | — | US | disclosed |
| WO-2017100819-A1 | MODULAR SYNTHESES OF DISCOIPYRROLE TYPE ALKALOIDS AND ANALOGUES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2017-06-22 | — | — | WO | disclosed |
| CN-1653042-A | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1066449-C | Tricyclic oxime ethers, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-05-30 | — | — | CN | disclosed |
| US-5627203-A | INHIBITORS OF SEROTONIN REUPTAKE, HIGH AFFINITY FOR 5HT RECEPTORS, ANXIOLYTIC, ANTIDEPRESSANT | ADIR ET COMPAGNIE (FR) | 1997-05-06 | — | — | US | disclosed |
| CN-1131155-A | Tricyclic oxime ethers, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-09-18 | — | — | CN | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4758559-A | Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172530-A1 | Small Molecule Sensitization of BAX Activation for Induction of Cell Death | BAX, BAD, TMBIM6 | KMT2A 4840/4885MYC 114/4885ALDH1A1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.